TY - JOUR
T1 - Monitoring Coronavirus Disease 2019
T2 - A Review of Available Diagnostic Tools
AU - Liu, Shanshan
AU - Li, Qiuyue
AU - Chu, Xuntao
AU - Zeng, Minxia
AU - Liu, Mingbin
AU - He, Xiaomeng
AU - Zou, Heng
AU - Zheng, Jianghua
AU - Corpe, Christopher
AU - Zhang, Xiaoyan
AU - Xu, Jianqing
AU - Wang, Jin
N1 - Funding Information:
This research was supported by a grant from the Science and Technology Commission of Shanghai (20Y11900700), a grant from the Special Research Fund of Youan Medical Alliance for the Liver and Infectious Diseases (LM202020), a grant from the National Special Research Program of China for Important Infectious Diseases (2018ZX10302103-003), and a grant from the National Natural Science Foundation of China (81672383).
Publisher Copyright:
© Copyright © 2021 Liu, Li, Chu, Zeng, Liu, He, Zou, Zheng, Corpe, Zhang, Xu and Wang.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/7
Y1 - 2021/6/7
N2 - Coronavirus disease 2019 (COVID-19) pneumonia is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has rapidly become a global public health concern. As the new type of betacoronavirus, SARS-CoV-2 can spread across species and between populations and has a greater risk of transmission than other coronaviruses. To control the spread of SARS-CoV-2, it is vital to have a rapid and effective means of diagnosing asymptomatic SARS-CoV-2-positive individuals and patients with COVID-19, an early isolation protocol for infected individuals, and effective treatments for patients with COVID-19 pneumonia. In this review, we will summarize the novel diagnostic tools that are currently available for coronavirus, including imaging examinations and laboratory medicine by next-generation sequencing (NGS), real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) analysis, immunoassay for COVID-19, cytokine and T cell immunoassays, biochemistry and microbiology laboratory parameters in the blood of the patients with COVID-19, and a field-effect transistor-based biosensor of COVID-19. Specifically, we will discuss the effective detection rate and assay time for the rRT-PCR analysis of SARS-CoV-2 and the sensitivity and specificity of different antibody detection methods, such as colloidal gold and ELISA using specimen sources obtained from the respiratory tract, peripheral serum or plasma, and other bodily fluids. Such diagnostics will help scientists and clinicians develop appropriate strategies to combat COVID-19.
AB - Coronavirus disease 2019 (COVID-19) pneumonia is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has rapidly become a global public health concern. As the new type of betacoronavirus, SARS-CoV-2 can spread across species and between populations and has a greater risk of transmission than other coronaviruses. To control the spread of SARS-CoV-2, it is vital to have a rapid and effective means of diagnosing asymptomatic SARS-CoV-2-positive individuals and patients with COVID-19, an early isolation protocol for infected individuals, and effective treatments for patients with COVID-19 pneumonia. In this review, we will summarize the novel diagnostic tools that are currently available for coronavirus, including imaging examinations and laboratory medicine by next-generation sequencing (NGS), real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) analysis, immunoassay for COVID-19, cytokine and T cell immunoassays, biochemistry and microbiology laboratory parameters in the blood of the patients with COVID-19, and a field-effect transistor-based biosensor of COVID-19. Specifically, we will discuss the effective detection rate and assay time for the rRT-PCR analysis of SARS-CoV-2 and the sensitivity and specificity of different antibody detection methods, such as colloidal gold and ELISA using specimen sources obtained from the respiratory tract, peripheral serum or plasma, and other bodily fluids. Such diagnostics will help scientists and clinicians develop appropriate strategies to combat COVID-19.
KW - COVID-19
KW - COVID-19 Testing
KW - Clinical Laboratory Techniques
KW - Humans
KW - SARS-CoV-2
KW - Sensitivity and Specificity
UR - http://www.scopus.com/inward/record.url?scp=85108609903&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2021.672215
DO - 10.3389/fpubh.2021.672215
M3 - Review article
C2 - 34164371
SN - 2296-2565
VL - 9
SP - 672215
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 672215
ER -